Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].
- Citation:
- ESMO Open vol 9 (11) 103938
- Year:
- 2024
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, UG1CA232760; UG1CA233180, UG1CA233196, UG1CA233329, UG1CA233337, U10CA180820 (ECOG-ACRIN); U10CA180863 (Canadian Clinical Trials Group) and grant 704970 from the Canadian Cancer Society; U10CA180888 (SWOG)
- Corr. Author:
- Authors:
- E de Azambuja M Piccart-Gebhart S Fielding J Townend D W Hillman M Colleoni R Roylance C M Kelly J Lombard S El-Abed A Choudhury L Korde M Vicente S Chumsri R Rodeheffer S L Ellard A C Wolff J Holtschmidt I Lang M Untch F Boyle B Xu G Werutsky J Tujakowski C-S Huang N B Baruch J Bliss A Ferro J Gralow S-B Kim J R Kroep I Krop S Kuemmel R McConnell L Moscetti A S Knop F van Duijnhoven H Gomez D Cameron S Di Cosimo R D Gelber A Moreno-Aspitia
- Networks:
- AL068, LAPS-CT018, LAPS-MA036, LAPS-MD017, LAPS-MN026, SC019
- Study
- NCCTG-N063D
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: